Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington’s Disease

Cells, Journal Year: 2022, Volume and Issue: 11(17), P. 2662 - 2662

Published: Aug. 27, 2022

Huntington’s disease (HD) is a rare neurodegenerative that accompanied by skeletal muscle atrophy and cardiomyopathy. Tissues affected HD (central nervous system [CNS], muscle, heart) are known to suffer from deteriorated cellular energy metabolism manifests already at presymptomatic stages. This work aimed test the effects of peroxisome proliferator-activated receptor (PPAR)-γ agonist—rosiglitazone on grip strength heart function in an experimental model—on R6/1 mice address mechanisms. We noted rosiglitazone treatment lead improvement cardiac mechanical function. It was enhancement total adenine nucleotides pool, increased glucose oxidation, changes mitochondrial number (indicated as citric synthase activity), reduction complex I activity. These metabolic were supported antioxidant status injected with rosiglitazone. Correction deficits further indicated decreased accumulation nucleotide catabolites serum. Thus, may not only delay neurodegeneration but also ameliorate cardio- myopathy linked energetics.

Language: Английский

---

Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 13

Published: Jan. 11, 2024

A series of seven clinical trials on relapsed or refractory (r/r) metastatic neoplasias followed the question: Are networks ligand-receptor cross-talks that support tumor-specific cancer hallmarks, druggable with tumor tissue editing approaches therapeutically exploiting plasticity? Differential recombinations pioglitazone, a dual peroxisome-proliferator activated receptor α/γ (PPARα/γ) agonist, transcriptional modulators, i.e., all-trans retinoic acid, interferon-α, dexamethasone plus metronomic low-dose chemotherapy (MCT) epigenetic modeling azacitidine plus/minus cyclooxygenase-2 inhibition initiated reprogramming as exemplified by inflammation control in r/r melanoma, renal clear cell carcinoma (RCCC), Hodgkin’s lymphoma (HL) and multisystem Langerhans histiocytosis (mLCH) differentiation induction non-promyelocytic acute myeloid leukemia (non-PML AML). Pioglitazone, integrated differentially designed schedules, facilitated death indicated complete remission (CR) non-PML AML, continuous CR RCCC, mLCH, HL addition everolimus, long-term disease melanoma efficaciously controlling metastasis, post-therapy repopulation acquired cell-resistance genetic/molecular-genetic heterogeneity (M-CRAC). PPARα/γ agonists provided tumor-type agnostic biomodulatory efficacy across different histologic neoplasias. Tissue techniques disclose wide-ranging functions may be on-topic focused for unlocking phenotypes. Low-dose MCT facilitates targeted hallmarks death, M-CRAC non-oncogene addiction. Thus, protocols, is an important drug addressing urgent therapeutic problems, such disease.

Language: Английский

---

Targeting Peroxisome Proliferator-Activated Receptor-β/δ, Reactive Oxygen Species and Redox Signaling with Phytocompounds for Cancer Therapy

Antioxidants and Redox Signaling, Journal Year: 2024, Volume and Issue: 41(4-6), P. 342 - 395

Published: Feb. 1, 2024

Peroxisome proliferator-activated receptors (PPARs) have a moderately preserved amino-terminal domain, an extremely DNA-binding integral hinge region, and distinct ligand-binding domain that are frequently encountered with the other nuclear receptors. PPAR-β/δ is among three receptor superfamily members in PPAR group.

Language: Английский

---

Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1650 - 1650

Published: July 24, 2024

Cardiovascular disease and cancer are the two leading causes of morbidity mortality in world. The emerging field cardio-oncology described several shared risk factors that predispose patients to both cardiovascular cancer. Post-acute COVID-19 syndrome is a chronic condition occurs many who have experienced SARS-CoV-2 infection, mainly based on fatigue, sedentary lifestyle, cramps, breathing difficulties, reduced lung performance. exposes increased visceral adiposity, insulin resistance, myosteatosis, white adipose tissue content (surrounded by M1 macrophages characterized Th1/Th17 phenotype), which increases recurrence. In this review, main metabolic affections post-acute at low high cardiomyopathies will be summarized. Furthermore, non-pharmacological strategies aimed reducing atherosclerotic cardiac provided, especially through anti-inflammatory nutrition with glycemic index, appropriate physical activity, immune-modulating bioactivities able reduce obesity improving insulin-related signaling myocardial metabolism.

Language: Английский

---

Editorial: Aldehyde dehydrogenase in clinical settings: Potential biomarker and therapeutic target in solid tumors

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 9

Published: Jan. 4, 2023

EDITORIAL article Front. Med., 04 January 2023Sec. Pathology Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.1116908

Language: Английский

---